Somewhat Positive Press Coverage Somewhat Unlikely to Impact Eli Lilly and (NYSE:LLY) Stock Price
News coverage about Eli Lilly and (NYSE:LLY) has been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eli Lilly and earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.7269827502901 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Fort Wayne native and Eli Lilly researcher carries message of life beyond cancer – News Sentinel (news-sentinel.com)
- Chartists Placing Eli Lilly and Co (LLY) on Their Radar – Evergreen Caller (evergreencaller.com)
- Eli Lilly and Company (NYSE:LLY) Trading Volume Significantly Lower – Modern Readers (modernreaders.com)
- Eli Lilly and (LLY) & SCYNEXIS (SCYX) Critical Analysis (americanbankingnews.com)
- Analysts Anticipate Eli Lilly and Company (NYSE:LLY) to Announce $1.04 EPS (americanbankingnews.com)
A number of research analysts have issued reports on the company. BidaskClub upgraded Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Barclays PLC boosted their price target on Eli Lilly and from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 4th. BMO Capital Markets reiterated a “sell” rating and set a $73.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. Berenberg Bank reiterated a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a research report on Thursday, July 27th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $96.00 price target (up previously from $93.00) on shares of Eli Lilly and in a research report on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $88.27.
Shares of Eli Lilly and (NYSE:LLY) traded up 0.73% during midday trading on Wednesday, hitting $82.57. The stock had a trading volume of 2,392,098 shares. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $86.72. The stock has a market capitalization of $87.11 billion, a price-to-earnings ratio of 35.73 and a beta of 0.34. The stock has a 50 day moving average price of $83.03 and a 200-day moving average price of $81.54.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.86 EPS. Equities research analysts anticipate that Eli Lilly and will post $4.16 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is presently 90.04%.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 215,000 shares of Eli Lilly and stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total value of $17,855,750.00. Following the sale, the insider now owns 124,475,804 shares of the company’s stock, valued at approximately $10,337,715,522.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the sale, the vice president now directly owns 62,056 shares in the company, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. Insiders sold a total of 669,733 shares of company stock worth $55,845,287 in the last three months. Company insiders own 0.20% of the company’s stock.
WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Eli Lilly and (NYSE:LLY) Stock Price” was posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-eli-lilly-and-nyselly-stock-price/1466524.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.